|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Departments of Lymphoma and Myeloma, Head and
Neck Surgery, and Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center, and the Department of Pathology, Baylor College
of Medicine, Houston, TX.
The malignant Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin
disease (HD) express several members of the tumor necrosis factor (TNF)
receptor family, including CD30 and CD40, and secrete several cytokines
and chemokines. However, little is known about what regulates cytokine
and chemokine secretion in H/RS cells. Although H/RS cells are
predominantly of B-cell origin, they frequently share phenotypic and
functional features with dendritic cells (DCs). Previous studies
reported that receptor activator of nuclear factor The pathology of Hodgkin disease (HD)1
is unique among human cancers. In a lymph node that is involved with
HD, the malignant cells known as Hodgkin and Reed-Sternberg (H/RS)
cells compose less than 1% of the tumor mass, with the remaining cells
being benign infiltrating T and B lymphocytes, monocytes, eosinophils, macrophages, and dendritic cells (DCs).1 The H/RS cells
secrete a wide variety of cytokines and chemokines that are believed to contribute to H/RS cell survival and to be involved in the chemotaxis of the infiltrating cells, the immune deficiency associated with the
disease, and the symptoms that are frequently observed in patients with
HD.2-7 Although molecular studies showed that the majority
of H/RS cells are derived from germinal center B lymphocytes, in rare
cases T lymphocytes can also be the cells of origin.8,9 Additionally, several studies have reported that H/RS cells may share
common features with DCs, including the expression of CD21, fascin, and
CD83.10-12
Receptor activator of nuclear factor Two receptors for RANKL have been identified: RANK and osteoprotegrin
(OPG).13,22 RANK is a member of the TNF receptor superfamily that shares the highest sequence homology with the extracellular domain of CD40.13 RANK messenger RNA (mRNA)
is ubiquitously expressed in human tissues, but RANK protein expression has been detected only in DCs, CD4 and CD8 T lymphocytes, and osteoclast hematopoietic precursor cells, suggesting that expression of
the protein is posttranscriptionally regulated.13,23 Like other TNF receptor family members, RANK activates several signaling pathways by interacting with various TNF receptor-associated factors (TRAFs).24-26 The signaling pathways activated by RANK
include NF- Osteoprotegerin is a secreted receptor that binds to both RANKL
and TNF-related apoptosis inducing ligand
(TRAIL)/Apo-2L.22,29 OPG mRNA is primarily
detected in the heart, placenta, lung, and kidney tissues. OPG inhibits
RANKL effects on osteoclasts in vitro and in vivo, and
OPG The expression and function of RANKL, RANK, and OPG in human
hematopoietic cancer cells and the function of RANK in malignant cells
are unknown. Because of the similarities between H/RS cells and DCs,
and because H/RS cells secrete a wide variety of cytokines that have
been shown to be induced by RANKL, we examined the expression of RANK
in cultured H/RS cells and determined the function of this expression.
Cell lines and reagents
Recombinant human RANKL, CD40 ligand (CD40L, CD154), and
activating antibody to human Fas (CH-11), soluble CD30, soluble RANK, and soluble OPG were from Alexis (San Diego, CA). Recombinant human
TRAIL trimer (leucine zipper) and activating antibody to human CD30
receptor (M44)32 were kindly provided by Dr Raymond Goodwin (Immunex, Seattle, WA). Antibodies to RANK, RANKL, and OPG were
from Imgenex (San Diego, CA); to Bcl-x, Bcl-2, Bax, and cellular
inhibitors of apoptosis proteins 2 (cIAP2) were from Santa Cruz
Biotechnology (Santa Cruz, CA); to cFLIP and cIAP1, survivin, and NAIP
were from R & D Systems (Minneapolis, MN); to XIAP was from
Transduction Laboratories (San Diego, CA); and to Assessment of cell viability
Flow cytometry Cells were stained with fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated antibodies to CD30, CD40, CD95 (Fas), CD154 (CD40L), B7.1, B7.2, or isotypic-matched control antibodies (all from Pharmingen, San Diego, CA) as previously described.34,35 Data were collected on a Becton Dickinson FACScan flow cytometer and analyzed by WinMDI 2.8 software (Joseph Trotter, Scripps, San Diego, CA).Western blot analysis Cellular protein was extracted by incubation in RIPA buffer (Roche Molecular Biochemicals, Indianapolis, IN) for 15 minutes at 4°C and then centrifuged to remove cellular debris. The protein in the resulting supernatant was quantified by the bicinchoninic acid (BCA) method according to the manufacturer's instructions (Pierce, Rockford, IL), diluted 1:1 in protein-loading buffer (0.25 M Tris-HCl, 2% sodium dodecyl sulfate [SDS], 4% -mercaptoethanol, 1% glycerol, and 0.2 mg/mL bromophenol blue), and boiled for 30 minutes. A total of 30 µg protein was loaded onto 12% Tris-HCl SDS-polyacrylamide gel electrophoresis (SDS-PAGE) Ready Gels (Bio-Rad, Hercules, CA), transferred to a nitrocellulose transfer membrane (Osmonics, Minnetonka, MN), and detected using ECL-Plus
(Amersham, Buckinghamshire, United Kingdom).
Electromobility shift assay and antibody supershift assay Electromobility shift assays (EMSAs) were performed to determine the activation and nuclear translocation of NF- B as previously described, with minor modifications.36 Briefly, 4 µg
nuclear protein extract was incubated with 16 fmol of a
32P-labeled 45-mer double-stranded DNA oligonucleotide
derived from the human immunodeficiency virus long terminal repeat
(5'-TTGTTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGG-3') (underlined areas indicate NF-B binding sites) for 30 minutes at 37°C. The resulting complex was resolved from free
oligonucleotide by electrophoresis on 6.6% native polyacrylamide gels.
To determine the specificity of NF-B, antibody supershift assays
were performed as previously described.37 Briefly, nuclear
protein extract was incubated with antibodies against different NF-B
subunits (p50 and p65), control antibody (cyclin-D1), preimmune serum
(PIS), unlabeled oligonucleotide, and mutant oligonucleotide:
5'-TTGTTACAACTCACTTTCCGCTGCTCACTTTCCAGGGAGGCGTGG-3') for 30 minutes and then assessed for NF-B by EMSA.
RNase protection assay The mRNA expression of cytokines and their receptors plus chemokines and their receptors was determined by RNase protection assay using RiboQuant kits from Pharmingen. Briefly, cell lines (0.5 × 106/mL) were incubated with RPMI or RANKL (1 µg/mL) for 24 hours. Total RNA was isolated from 1 × 107 cells using the guanidium-isothiocyanate method. Ten micrograms of RNA from each sample was hybridized to a 32P-labeled antisense probe set (hCR-1, hCR-5, hCK-1, hCK-5, hCR-6, h-APO-3d) and digested with RNase and T1 nuclease. The protected probe fragments were resolved on 5% polyacrylamide gels according to the manufacturer's instructions. Band intensity was quantified by National Institutes of Health image software (version 1.6.1) and normalized to the intensity of GAPDH probe.Immunohistochemistry Paraffin-embedded lymph node biopsy sections from patients with nodular sclerosis HD were immunostained using a Techmate 1000 automatic immunostainer (Ventana, Tucson, AZ) as described previously.38 Briefly, sections were deparaffinized in xylene, rehydrated with decreasing concentrations of alcohol and finally phosphate-buffered saline (PBS), and subjected to steam-heat epitope retrieval in 10 mM citrate buffer (pH 6.0) for 30 minutes in a commercially available vegetable steamer. The sections were then rinsed in distilled water, washed in PBS for 5 minutes, and incubated for 15 minutes with DAKO protein block (DAKO, Carpenteria, CA). Next, they were incubated for 2 hours with anti-RANK monoclonal antibody from Alexis, diluted 1:500 in 0.1% bovine serum albumin/PBS. (Results were confirmed using a polyclonal antibody from Santa Cruz diluted at 1:50.) Then sections were washed, and bound antibodies were detected using an LSAB2 peroxidase kit (primary rabbit/mouse; DAKO) with diaminobenzidine as chromogen. Finally, the sections were counterstained with hematoxylin, dehydrated, and mounted. Negative controls were biopsy sections that were immunostained with either nonreactive mouse IgG diluted to the same concentration as the anti-RANK antibody or with no antibody. Results of CD30, CD15, CD20, and LMP-1 expression in primary H/RS cells were available from pre-existing diagnostic reports in 7 patients.Enzyme-linked immunosorbent assay Human IL-8 and IL-13 levels were determined in H/RS cell supernatants, after incubation with RANKL (2 µg/mL), soluble RANK (5 µg/mL), or both. Incubations were performed for 24 to 48 hours. Commercially available enzyme-linked immunosorbent assay (ELISA) kits from R & D Systems were used according to the manufacturer's instructions. The lower limit of sensitivity of this assay is 10 pg/mL for IL-8 and 32 pg/mL for IL-13. The results were read at an optical density of 450 nm using a Vmax ELISA reader (Molecular Devices, Menlo Park, CA). Measurements were done in triplicate and results are reported as the mean ± SD.
Functional expression of RANK in H/RS cells We examined the expression of RANKL and its 2 receptors, RANK and OPG, in 4 well-characterized H/RS cell lines using Western blot analysis. The RANK protein was most prominently expressed in HDLM-2 and L-428 cells, with lower expression observed in HD-MYZ and KM-H2 cell lines (Figure 1A). All cell lines expressed RANK at the mRNA level as determined by real-time polymerase chain reaction (PCR) assay (data not shown). RANKL and OPG were expressed in all 4 HD cell lines (Figure 1A). Results were then were compared with those of other cell lines of hematopoietic origin (Table 1). In these cell lines, RANK was most prominently expressed by the multiple myeloma cell line 8226 and was weakly expressed by the T lymphoblastic Jurkat cell line and the anaplastic large cell lymphoma DHL-1 cell line. As shown in Table 1, the phenotype of the cell line (B or T), the expression of CD30, CD40, or Epstein-Barr virus (EBV) did not correlate with RANK expression. All these cell lines expressed OPG, whereas RANKL was expressed in 7 of the 9 cell lines tested (Table 1).
Expression of RANK was also evaluated in primary lymphoid tumors
(Figures 1B and 2). Using Western blot
analysis, RANK expression could not be detected in 5 primary
non-Hodgkin lymphoma specimens, regardless of their phenotype (Figure
1B). In contrast, RANKL and OPG were variably expressed in all these
specimens. Using immunohistochemestry, RANK was detected in primary
H/RS cells in 10 lymph node sections (Figure 2A,B), but was rarely and
weakly expressed in sections from small lymphocytic lymphoma (Figure 2C) or from a benign hyperplastic lymph node (Figure 2D). Within each
lymph node section, an average of 75% of H/RS cells (range 10% to
> 75%) expressed RANK (Table 2), which
showed a predominantly cytoplasmic staining pattern (Figure 2), but it
was rarely, but weakly, expressed in the benign infiltrating cells
(Figure 2A,B). There was no difference in the pattern or frequency of
RANK expression in cases of nodular sclerosis or mixed cellularity
(Table 2). C30, CD15, CD20, or LMP-1 expression data were available on
7 of the 10 primary HD sections (3 nodular sclerosis and 4 mixed cellularity), and no correlation could be found between RANK expression and the expression of these antigens (Table 2).
RANK was previously reported to activate NF-
Effect of RANKL on cultured H/RS cell survival in vitro RANKL has been reported to be a survival factor for DCs.23 To investigate whether RANKL plays a similar role in H/RS cells, we incubated these 4 cell lines with increasing concentrations of RANKL (0-1000 ng/mL) for 24 to 72 hours. Cell viability and proliferation were determined using the MTS assay. RANKL had no significant effect on the survival or proliferation of any of the H/RS cell lines in vitro (Figure 4A).
Because these cell lines coexpressed RANKL and RANK, we hypothesized that these cells may have been maximally stimulated with endogenous RANKL through an autocrine survival loop. Therefore, we reasoned that if we interrupted this loop, we might decrease cell survival. To test this hypothesis, we incubated H/RS cell lines with increasing concentrations of soluble RANK and soluble OPG. H/RS cells incubated with soluble CD30 were used as a control. At concentrations ranging from 5 to 500 ng/mL neither soluble RANK nor OPG had an effect on H/RS cell survival in vitro (Figure 4B). The effect of RANKL on intracellular proteins that influence cell survival was subsequently investigated in the H/RS cell lines. Cells were incubated with RANKL (1 µg/mL) or medium for 24 or 48 hours and the levels of intracellular proteins were measured by Western blot analysis. RANKL had no effect on the expression of Bcl-xL, Bax, or Bcl-2 proteins (data not shown). Furthermore, RANKL had no effect on the antiapoptotic protein FLICE-inhibiting protein (cFLIP) or on any of the inhibitors of apoptosis proteins (IAPs) (data not shown). Although RANKL had no significant effect on the survival of cultured H/RS cells in vitro, we examined whether RANKL can modulate the apoptotic effect induced by chemotherapy, TRAIL, or Fas ligand. Cells were incubated with doxorubicin (0.5 µg/mL), RANK (1 µg/mL), or both for 24 or 48 hours and the viable cell number was determined using the MTS assay. Doxorubicin was effective in killing L-428, HDLM-2, and KM-H2 cells (data not shown). The combination of doxorubicin plus RANKL was not different from doxorubicin alone, indicating that RANKL could not inhibit doxorubicin-induced cell death in these H/RS cell lines. Similarly, RANKL had no effect on FasL- or TRAIL-induced cell death in the H/RS-sensitive cell lines (data not shown). Effect of RANKL on cell surface protein expression The H/RS cells frequently express TNF receptor family members, including CD30, CD40, and CD95.40 In addition, H/RS cells frequently express the costimulatory molecules B7.1 and B7.2. To determine whether RANKL is involved in regulating the expression of these proteins, cultured H/RS cell lines were incubated with recombinant RANKL (1 µg/mL) for 24 or 48 hours. Cell surface expression of these proteins was determined using FACS analysis. Among these 4 cell lines, only HD-MYZ cells did not express CD30 or CD40 (data not shown). The remaining cells expressed CD30, CD40, and CD95 (Fas) (data not shown). None of these cell lines expressed CD40 ligand (CD40L, CD154). When these cell lines were incubated with RANKL, no significant effect was observed on the expression of CD30, CD40, CD95, or CD154 (data not shown). Similarly, RANKL had no effect on B7.1, B7.2, or HLA-DR expression (data not shown).Because CD154 (CD40L) was reported to up-regulate RANK expression in human DCs,13 we examined the effect of CD154 and CD30 ligand (CD30L, CD153) on RANK expression in H/RS cell lines. H/RS cells were incubated with agonistic antibody to CD30 (M44, 10 µg/mL)32 or recombinant CD154 (1 µg/mL) for 24 or 48 hours. The expressions of RANKL and RANK were determined using Western blot analysis. Neither the activation of CD30 nor of CD40 had a significant effect on the expression of RANK or RANKL in these cell lines (data not shown). Effect of RANKL on cytokine and chemokine secretion One of the major features of H/RS cells is their ability to secrete a wide array of cytokines and chemokines.2-7 RANKL has been shown to enhance the secretion of several cytokines in DCs.21 To investigate whether RANKL can regulate the secretion of cytokines and chemokines in H/RS cell lines, we incubated these cell lines with RANKL (1 µg/mL) for 6 to 24 hours. The level of mRNA expression of different panels of cytokines, chemokines, and their receptors was determined using the RNase protection assay. The most prominent effect was observed on IL-8 expression in the HD-MYZ cell line (Figure 5A). After incubation with 1 µg/mL RANKL for 24 hours, IL-8 mRNA expression increased by 7-fold. A 2- to 3-fold increase in the mRNA expression of IL-15, IL-9, IL-13, and IL-13 receptor was observed in different H/RS cell lines (Figure 5B and Table 1). After 6 hours of incubation with RANKL, the mRNA expression of interferon- (IFN-), IL-9, IL-15, IL-15R , RANTES, CCR4, and IL-8 were increased in different cell lines (Table
3). However, after 6 hours of incubation
with RANKL, none of the HD cell lines showed any significant changes in
the mRNA levels for FasL or Fas, TRAIL or its receptors, FLICE, TRADD,
or FLIP (data not shown). After 24 hours of incubation with RANKL, none
of these cell lines showed a significant change in the mRNA expression
of the receptors for IL-7, IL-9, IL-15, IL-4, or IL-2; CCR-1, CCR-3,
CCR-4, CCR-5, CCR-8, or CCR-2 (partial data are shown in Figure 5B).
Furthermore, RANKL had no effect on the mRNA expression of IP-10,
macrophage inflammatory protein 1 (MIP-1), MIP-1, monocyte
chemotactic protein 1 (MCP-1), thymus- and activation-regulated
chemokine (TARC), IL-5, IL-4, IL-10 (human), or IL-14 in any of these
cell lines (data not shown).
Three H/RS cell lines produced detectable levels of IL-13 in the
culture supernatants. After 48 hours in culture, HDLM-2 produced a
basal level of 95 pg/mL, L-428 produced 55 pg/mL, and KMH-2 produced
150 pg/mL. In HDLM-2 cells, RANKL (2 µg/mL) increased the IL-13 level
from 96 ± 10 pg/mL to 340 ± 63 pg/mL, an effect that was
completely blocked by adding soluble RANK (5 µg/mL) to the culture
(Figure 6A). However, soluble RANK alone
had no effect on the basal level of IL-13.
The HD-MYZ cell line secreted high levels of IL-8 requiring 1:20 dilutions of the supernatants to perform the ELISA. In this cell line, soluble RANK decreased the basal level of IL-8 suggesting that IL-8 was induced by a RANKL/RANK autocrine loop (Figure 6B). Accounting for the 1:20 dilution factor, exogenous RANKL increased IL-8 from a basal value of 8500 ± 312 pg/mL to 11 720 ± 192 pg/mL within 24 hours, an effect that was blocked by soluble RANK.
In this paper we report that cultured H/RS cells express RANKL and
its 2 receptors, RANK and OPG. Our data add to the complex biologic
features of H/RS cells because these cells express several other
TNF family receptors including CD30, CD40, Fas, and
TNFR-1.40 In normal tissue, RANK mRNA is expressed in
skeletal muscles, colon and intestines, adrenal glands, and thymus,
whereas RANK protein is predominantly expressed by DCs, activated T
cells, and osteoclasts.23 Except for activated T cells
that can express RANKL and RANK, H/RS cells are now added to multiple
myeloma cells to be the only malignant cells that coexpress RANK and
RANKL. It is possible that the weak expression of RANK and RANKL in
Jurkat and DHL-1 cells may reflect their T-cell origin. It is
interesting to note that the majority of H/RS cells are derived from
germinal center B cells, with rare cases originating from T
lymphocytes.8,9 In this study we observed weak expression
of RANK in the benign hyperplastic germinal center cells, but the
physiologic role of this expression is unclear. However, this finding
may be related to the observation that RANK RANK was expressed by primary H/RS cells, but its expression was
rare among the benign infiltrating cells, perhaps reflecting their
inactivated status. In this study, RANK induced NF- The expressions of IL-13 and IL-13 receptor have been recently reported in cultured and primary H/RS cells and play a role in the survival of H/RS cells.3,42 Therefore, the ability of RANK to up-regulate both IL-13 and IL-13 receptor suggests that RANK may indirectly have a role in the growth regulation of H/RS cells. RANK may also play an important role in regulating the cellular infiltrate surrounding H/RS cells by regulating the expression of critical chemokines such as IL-8.43 In addition to the reported similarities between H/RS cells and DCs, we found new common features between these 2 cell types. Both cell types express RANK, and RANK activation induces the expression of several cytokines and chemokines. However, several important differences between H/RS cells and DCs were also observed in this study. First, DCs do not express RANKL. Second, unlike DCs, whereas RANK activation provides survival signals by up-regulating Bcl-xL,14 we found no role for RANK in regulating the survival or proliferation of the tested H/RS cell lines. RANK activation in H/RS cells did not regulate the expression of several intracellular proteins that are known to be involved in regulating cell life and death, including Bcl-xL, Bax, Bcl-2, cFLIP, and IAPs. Whether RANKL may provide survival signals to primary H/RS cells is currently unknown. In B cells, IL-13 and CD40L can inhibit apoptosis by up-regulating Bcl-xL.44 It is unknown whether RANKL may act synergistically with other survival factors such as IL-13, CD40L, or CD30L. Third, CD40L was reported to up-regulate RANK in DCs,13 but failed to do so in H/RS cells. In normal tissues, RANKL mRNA is detected in the thymus, lymph nodes, and resting CD4+ and CD8+ T lymphocytes. RANKL protein is expressed by osteoblasts, bone stromal cells, and activated T lymphocytes. In this study, all the H/RS cell lines expressed RANKL regardless of their phenotype (B, T, or monocytoid), in addition to 2 T-cell lines (Jurkat and SUP-M2) and a multiple myeloma B-cell line (8226). Interestingly, RANKL was also expressed by primary B and T lymphomas. The role of RANKL in these B- and T-cell primary lymphoma tumors remains unclear. The expression of RANK and RANKL in H/RS cells suggests that they may regulate cytokine and chemokine expression by an autocrine loop mechanism. In short-term culture, interrupting this autocrine loop by soluble RANK had no effect on H/RS cell survival. It is not known whether interrupting this autocrine loop may decrease the cellular infiltrate around primary H/RS cells. Although RANKL did not enhance HD cell survival, down-regulating certain cytokines and chemokines may indirectly influence H/RS cell survival by decreasing the cellular infiltrate that may provide survival signals. In conclusion, our study shows for the first time that RANK and RANKL are functionally expressed in H/RS cell lines and that RANK is expressed in primary H/RS cells. The expression of RANK and RANKL is likely to be involved in regulating the cellular infiltrate and cytokine and chemokine secretion in HD.
Submitted March 9, 2001; accepted June 6, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anas Younes, Department of Lymphoma and Myeloma, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: ayounes{at}mdanderson.org.
1. Kadin ME. Pathology of Hodgkin's disease. Curr Opin Oncol. 1994;6:456-463[Medline] [Order article via Infotrieve].
2.
Haluska FG, Brufsky AM, Canellos GP.
The cellular biology of the Reed-Sternberg cell.
Blood.
1994;84:1005-1019
3.
Kapp U, Yeh WC, Patterson B, et al.
Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.
J Exp Med.
1999;189:1939-1946
4.
Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G.
Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia.
Blood.
1999;93:2463-2470
5.
Gorschluter M, Bohlen H, Hasenclever D, Diehl V, Tesch H.
Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.
Ann Oncol.
1995;6:477-482
6.
Gruss HJ, Herrmann F, Drexler HG.
Hodgkin's disease: a cytokine-producing tumor
7.
Jundt F, Anagnostopoulos I, Bommert K, et al.
Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils.
Blood.
1999;94:2065-2071 8. Stein H, Hummel M. Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol. 1999;36:233-241[Medline] [Order article via Infotrieve].
9.
Staudt LM.
The molecular and cellular origins of Hodgkin's disease.
J Exp Med.
2000;191:207-212 10. Nakamura S, Nagahama M, Kagami Y, et al. Hodgkin's disease expressing follicular dendritic cell marker CD21 without any other B-cell marker: a clinicopathologic study of nine cases. Am J Surg Pathol. 1999;23:363-376[CrossRef][Medline] [Order article via Infotrieve]. 11. Sorg UR, Morse TM, Patton WN, et al. Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Pathology. 1997;29:294-299[CrossRef][Medline] [Order article via Infotrieve]. 12. Pinkus GS, Pinkus JL, Langhoff E, et al. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease: evidence for a dendritic or B cell derivation? Am J Pathol. 1997;150:543-562[Abstract]. 13. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179[CrossRef][Medline] [Order article via Infotrieve].
14.
Wong BR, Josien R, Lee SY, et al.
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.
J Exp Med.
1997;186:2075-2080 15. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176[CrossRef][Medline] [Order article via Infotrieve]. 16. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 1998;246:199-204[CrossRef][Medline] [Order article via Infotrieve]. 17. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323[CrossRef][Medline] [Order article via Infotrieve].
18.
Li J, Sarosi I, Yan XQ, et al.
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.
Proc Natl Acad Sci U S A.
2000;97:1566-1571
19.
Hsu H, Lacey DL, Dunstan CR, et al.
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.
Proc Natl Acad Sci U S A.
1999;96:3540-3545
20.
Josien R, Li HL, Ingulli E, et al.
TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo.
J Exp Med.
2000;191:495-502
21.
Josien R, Wong BR, Li HL, Steinman RM, Choi Y.
TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells.
J Immunol.
1999;162:2562-2568 22. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments]. Cell. 1997;89:309-319[CrossRef][Medline] [Order article via Infotrieve]. 23. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol. 1999;65:715-724[Abstract].
24.
Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB.
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK): interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase.
J Biol Chem.
1998;273:20551-20555
25.
Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC.
The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily.
J Biol Chem.
1998;273:34120-34127
26.
Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y.
The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor.
J Biol Chem.
1998;273:28355-28359 27. Arron JR, Choi Y. Bone versus immune system. Nature. 2000;408:535-536[CrossRef][Medline] [Order article via Infotrieve].
28.
Dougall WC, Glaccum M, Charrier K, et al.
RANK is essential for osteoclast and lymph node development.
Genes Dev.
1999;13:2412-2424
29.
Emery JG, McDonnell P, Burke MB, et al.
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
J Biol Chem.
1998;273:14363-14367
30.
Bucay N, Sarosi I, Dunstan CR, et al.
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Genes Dev.
1998;12:1260-1268 31. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells, II: continuous cell lines. Leuk Lymphoma. 1993;9:1-25[Medline] [Order article via Infotrieve]. 32. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73:1349-1360[CrossRef][Medline] [Order article via Infotrieve]. 33. Snell V, Clodi K, Zhao S, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997;99:618-624[CrossRef][Medline] [Order article via Infotrieve]. 34. Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol. 1998;103:270-275[CrossRef][Medline] [Order article via Infotrieve]. 35. Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol. 1998;103:217-219[CrossRef][Medline] [Order article via Infotrieve].
36.
Estrov Z, Manna SK, Harris D, et al.
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
Blood.
1999;94:2844-2853
37.
Giri DK, Aggarwal BB.
Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells: autocrine role of tumor necrosis factor and reactive oxygen intermediates.
J Biol Chem.
1998;273:14008-14014 38. Younes M, Lechago J, Ertan A, Finnie D, Younes A. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Hum Pathol. 2000;31:434-438[CrossRef][Medline] [Order article via&nbs |
B in Hodgkin disease cell lines
Top
Abstract
Introduction
/
a review.
Crit Rev Oncol.
1994;5:473-538.